Xanthine oxidoreductase depletion induces renal interstitial fibrosis through aberrant lipid and purine accumulation in renal tubules

Hypertension

Volumn 54, Issue 4, 2009, Pages 868-876

  Ohtsubo, Toshio ^a   Matsumura, Kiyoshi ^a   Sakagami, Kanae ^a   Fujii, Koji ^a   Tsuruya, Kazuhiko ^a   Noguchi, Hideko ^a   Rovira, Ilsa I ^b   Finkel, Toren ^b   Iida, Mitsuo ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Epithelial mesenchymal transition; Lipid; Oxidative stress; Renal interstitial fibrosis; Uric acid; Xanthine; Xanthine oxidoreductase

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; CCAAT ENHANCER BINDING PROTEIN ALPHA; CCAAT ENHANCER BINDING PROTEIN BETA; FATTY ACID SYNTHASE; HYPOXANTHINE; LIPID; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PURINE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TRANSFORMING GROWTH FACTOR BETA; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; VIMENTIN; XANTHINE; XANTHINE OXIDASE;

ADIPOGENESIS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; GENE DELETION; GENE DISRUPTION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY ISCHEMIA; KIDNEY TUBULE; LIPID STORAGE; MOUSE; MYOFIBROBLAST; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; URINARY EXCRETION; WESTERN BLOTTING;

ADIPOGENESIS; ANIMALS; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; FEMALE; FIBROSIS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE (PHOSPHORYLATING); HYPOXANTHINE; KIDNEY TUBULES; LIPID METABOLISM; LIPOGENESIS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NEPHRITIS, INTERSTITIAL; OXIDATIVE STRESS; PURINES; TRIGLYCERIDES; XANTHINE; XANTHINE DEHYDROGENASE;

EID: 70349672857     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.135152     Document Type: Article

References (39)

1. Schardinger F. Ueber das Verhalten der Kuhmilch gegen Methylblau und seine Verwendung zur Unterscheidung von ungekochter und gekochter Milch. Z Untersuch Nahrungs Genussmittel. 1902;5:1113-1121.
2. Harrison R. Structure and function of xanthine oxidoreductase: where are we now. Free Radic Biol Med. 2002;33:774-797.
3. Meneshian A, Bulkley GB. The physiology of endothelial xanthine oxidase: from urate catabolism to reperfusion injury to inflammatory signal transduction. Microcirculation. 2002;9:161-175.
4. Granger DN, Rutili G, McCord JM. Superoxide radicals in feline intestinal ischemia. Gastroenterology. 1981;81:22-29.
5. Vorbach C, Harrison R, Capecchi MR. Xanthine oxidoreductase is central to the evolution and function of the innate immune system. Trends Immunol. 2003;24:512-517.
6. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516-521.
7. McManaman JL, Palmer CA, Wright RM, Neville MC. Functional regulation of xanthine oxidoreductase expression and localization in the mouse mammary gland: evidence of a role in lipid secretion. J Physiol. 2002;545:567-579.
8. Cheung KJ, Tzameli I, Pissios P, Rovira I, Gavrilova O, Ohtsubo T, Chen Z, Finkel T, Flier JS, Friedman JM. Xanthine oxidoreductase is a regulator of adipogenesis and PPARgamma activity. Cell Metab. 2007;5: 115-128.
9. Ichida K, Amaya Y, Kamatani N, Nishino T, Hosoya T, Sakai O. Identification of two mutations in human xanthine dehydrogenase gene responsible for classical type I xanthinuria. J Clin Invest. 1997;99: 2391-2397.
10. Ohtsubo Y, Rovira II, Starost MF, Liu C, Finkel T. Xanthine oxidoreductase is an endogeneous regulator of cyclooxygenase-2. Circ Res. 2004;95:1118-1124.
11. Dinchuk JE, Car BD, Focht RJ, Johnston JJ, Jaffee BD, Covington MB, Contel NR, Eng VM, Collins RJ, Czerniak PM, Gorry SA, Trzaskos JM. Renal abnormalities and an altered inflammatory response in mice lacking cyclooxygenase II. Nature. 1995;378:406-409.
12. Morham SG, Langenbach R, Loftin CD, Tiano HF, Vouloumanos N, Jennette JC, Mahler JF, Kluckman KD, Ledford A, Lee CA, Smithies O. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell. 1995;83:473-482.
13. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;283:F861-F875.
14. Anderson FS, Murphy RC. Isocratic separation of some purine nucleotide, nucleoside, and base metabolites from biological extracts by highperformance liquid chromatography. J Chromatogr. 1976;121:251-262.
15. Bligh E, Dyer W. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959;37:911-917.
16. Tsuruya K, Furuichi M, Tominaga Y, Shinozaki M, Tokumoto M, Yoshimitsu T, Fukuda K, Kanai H, Hirakata H, Iida M, Nakabeppu Y. Accumulation of 8-oxoguanine in the cellular DNA and the alteration of the OGG1 expression during ischemia-reperfusion injury in the rat kidney. DNA Repair. 2003;2:211-229.
17. Ohtsubo T, Ohya Y, Nakamura Y, Kansui Y, Furuichi M, Matsumura K, Fujii K, Iida M, Nakabeppu Y. Accumulation of 8-oxo-deoxyguanosine in cardiovascular tissues with the development of hypertension. DNA Repair. 2007;6:760-769.
18. -/-) mice. Proc Natl Acad Sci U S A. 2006;103: 7165-7169.
19. Ohtsubo T, Nishioka K, Imaiso Y, Iwai S, Shimokawa H, Oda H, Fujiwara T, Nakabeppu Y. Identification of human MutY homolog (hMYH) as a repair enzyme for 2-hydroxyadenine in DNA and detection of multiple forms of hMYH located in nuclei and mitochondria. Nucleic Acids Res. 2000;28:1355-1364.
20. Terryn S, Jouret F, Vandenabeele F, Smolders I, Moreels M, Devuyst O, Steels P, Van Kerkhove E. A primary culture of mouse proximal tubular cells, established on collagen-coated membranes. Am J Physiol Renal Physiol. 2007;293:F476-F485.
21. Kean RB, Spitsin SV, Mikheeva T, Scott GS, Hooper DC. The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity. J Immunol. 2000;165:6511-6518.
22. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78:6858-6862.
23. Xu P, Vallee PL, Hoidal JR. Repressed expression of the human xanthine oxidoreductase gene. J Biol Chem. 2000;275:5918-5926.
24. Yelandi AV, Chu R, Pan J, Zhu Y, Usuda N. Peroxisomal purine metabolism. Ann N Y Acad Sci. 1996;804:165-175.
25. Mateos FA, Puig JG, Jimenez ML, Fox IH. Hereditary xanthinuria: evidence for enhanced hypoxanthine salvage. J Clin Invest. 1987;79: 847-852.
26. Koseki C, Herzlinger D, Al-Awqati Q. Apoptosis in metanephric development. J Cell Biol. 1992;119:1327-1333.
27. Zager RA, Johnson AC, Hanson SY. Renal tubular triglyercide accumulation following endotoxic, toxic, and ischemic injury. Kidney Int. 2005; 67:111-121.
28. Kume S, Uzu T, Araki S, Sugimoto T, Isshiki K, Chin-Kanasaki M, Sakaguchi M, Kubota N, Terauchi Y, Kadowaki T, Haneda M, Kashiwagi A, Koya D. Role of altered renal lipid metabolism in the development of renal injury induced by a high-fat diet. J Am Soc Nephrol. 2007;18: 2715-2723.
29. Gwinner W, Scheuer H, Haller H, Brandes RP, Groene HJ. Pivotal role of xanthine oxidase in the initiation of tubulointerstitial renal injury in rats with hyperlipidemia. Kidney Int. 2006;69:481-487.
30. Pfeffer KD, Huecksteadt TP, Hoidal JR. Xanthine dehydrogenase and xanthine oxidase activity and gene expression in renal epithelial cells: cytokine and steroid regulation. J Immunol. 1994;153:1789-1797.
31. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol. 2004;15:1-12.
32. Johnson RJ, Kang DH, Feig D, Kivlighn S, Kanellis J, Watanabe S, Tuttle KR, Rodriguez-Iturbe B, Herrera-Acosta J, Mazzali M. Is there a pathogenetic role for uric acid in hypertension and cardiovascular and renal disease? Hypertension. 2003;41:1183-1190.
33. Nakagawa T, Kang DH, Feig D, Sanchez-Lozada LG, Srinivas TR, Sautin Y, Ejaz AA, Segal M, Johnson RJ. Unearthing uric acid: an ancient factor with recently found significance in renal and cardiovascular disease. Kidney Int. 2006;69:1722-1725.
34. Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51-59.
35. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev. 2006;58:87-114.
36. Hajjar RJ, Leopold JA. Xanthine oxidase inhibition and heart failure: novel therapeutic strategy for ventricular dysfunction? Circ Res. 2006; 98:169-171.
37. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: the PIUMA Study. Hypertension. 2000; 36:1072-1078.
38. Lehto S, Niskanen L, Ronnemaa T, Laakso M. Serum uric acid is a strong predictor of stroke in patients with non-insulin-dependent diabetes mellitus. Stroke. 1998;29:635-639.
39. Suliman ME, Johnson RJ, García-López E, Qureshi AR, Molinaei H, Carrero JJ, Heimbürger O, Bárány P, Axelsson J, Lindholm B, Stenvinkel P. J-shaped mortality relationship for uric acid in CKD. Am J Kidney Dis. 2006;48:761-771.